Cubist Pharmaceuticals Announces Third Quarter 2009 Earnings Call.Earnings Conference Call & Webcast on Thursday, October 15(th), at 5:00 pm ET LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ) today announced that it will issue its third quarter 2009 financial results at 4:00 p.m. ET on Thursday, October 15th, 2009. In connection with this announcement, Cubist will host a conference call and webcast (with slides) at 5:00 p.m. ET on the same day to discuss its third quarter financial results, business activities, and financial outlook. As always, the quarterly earnings call will be available via phone and webcast. The phone call dial-in information is listed below. To access the webcast, please log on to the Cubist website at cubist.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. A replay of the webcast and teleconference will be available on Cubist's website [for 30 days] beginning approximately three hours after the call. ***************************************************************************** Your Teleconference Information: Event Date: 10/15/2009 Event Time: 5:00 PM Eastern Event Title: Third Quarter 2009 Earnings Call Participant Dial-In Numbers: 877-407-8289 For more information: http://www.investorcalendar.com/IC/CEPage.asp?ID=149453 Replay / archive access is here: (877) 660-6853 (Toll free) (201) 612-7415 (Local / Int'l) Acct. #: 351 Conference ID: 332096 ***************************************************************************** About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN[R] (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM[R] I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials phase 2 clinical trial Phase 2 study. See Phase study. -- CONSERV[TM]-1 and CONSERV[TM]-2 -- for the reduction of blood loss during cardiac surgery Cardiac surgery is surgery on the heart and/or great vessels performed by a cardiac surgeon. Frequently, it is done to treat complications of ischemic heart disease (for example, coronary artery bypass grafting), correct congenital heart disease, or treat valvular heart disease , and two Phase 1 programs that address unmet medical needs, one in CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator (Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. difficile-associated diarrhea) and the other in multi-drug resistant (MDR MDR, n See multidrug resistance. MDR, n the abbreviation for minimum daily requirement, specifically the Minimum Daily Requirements for Specific Nutrients compiled by the United States Food and Drug Administration. ) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. , Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections Respiratory Syncytial Virus Infection Definition Respiratory syncytial virus (RSV) is a virus that can cause severe lower respiratory infections in children under the age of two, and milder upper respiratory infections in older children and adults. using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com. Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion